Magnesium-containing products and uses thereof

Abstract

A composition including a hydrate form of magnesium oxide, denoted as MgO.(H 2 O)n, at a concentration ranging from 1 to 100 weight percent (wt %), where n is any value from 0.1 to 2. The composition may further include MgO at a concentration ranging from 0 to 99 wt %; or Mg(OH) 2 , at a concentration ranging from 0 to 99 wt %; or Mg(OH) 2 at a concentration ranging from 0 to 99 wt %, and MgO, at a concentration ranging from 0 to 99 wt %.

What is claimed is: 
     
         1 . A method of treating a condition selected from the group consisting of coronary artery disease (CAD), heart failure, a cardiovascular disease, an ischemic heart disease and cardiac arrhythmia, the method comprising orally administering to a subject in need thereof a therapeutically effective amount of a composition comprising a hydrate form of magnesium oxide, denoted as MgO.(H 2 O)n, at a concentration in a range of from 1 to 100 weight percent (wt %), where n is any value from 0.1 to 2. 
     
     
         2 . The method of  claim 1 , wherein orally administering the composition is effected daily. 
     
     
         3 . The method of  claim 1 , wherein an amount of elemental magnesium in said therapeutically effective amount is in a range of from 500 mg to 2000 mg. 
     
     
         4 . The method of  claim 1 , wherein said composition comprises:
 Magnesium oxide hydrate MgO.(H 2 O)n, at a concentration in a range of from 1 to 100 wt %, wherein n in any value from 0.1 to 2, and MgO at a concentration in a range of from 0 to 99 wt %; or   Magnesium oxide hydrate MgO.(H 2 O)n, at a concentration in a range of from 1 to 100 wt %, wherein n in any value from 0.1 to 2, and Mg(OH) 2 , at a concentration in a range of from 0 to 99 wt %; or   Magnesium oxide hydrate MgO.(H 2 O)n, at a concentration in a range of from 1 to 100 wt %, wherein n is any value from 0.1 to 2, Mg(OH) 2  at a concentration in a range of from 0 to 99 wt %, and MgO at a concentration in a range of from 0 to 99 wt %.   
     
     
         5 . The method of  claim 1 , wherein n is in a range of from 0.3 to 1. 
     
     
         6 . The method of  claim 1 , wherein a concentration of said MgO.(H 2 O)n in said composition is selected from the group including: at least 10 wt %, at least 20 wt %, at least 30 wt %, at least 40 wt %, at least 50 wt %, at least 60 wt %, at least 70 wt % or at least 80 wt % of a total weight of the composition. 
     
     
         7 . The method of  claim 1 , wherein said composition is in a form of a plurality of particles, and said particles have a BET surface area in a range of from 30 m 2 /gram to 40 m 2 /gram. 
     
     
         8 . The method of  claim 1 , wherein said composition is formulated as a unit dosage form for oral administration, wherein an amount of elemental magnesium in said unit dosage form is in a range of from 50 mg to 2000 mg, wherein said unit dosage form is administered daily. 
     
     
         9 . The method of  claim 1 , wherein said composition is characterized as capable of generating free magnesium ions from at least 50% of said composition, under physiological conditions of a human stomach and/or in an acidic aqueous solution for 45 minutes at room temperature. 
     
     
         10 . A method of abrogating, substantially inhibiting, slowing or reversing a progression of a condition, substantially ameliorating clinical symptoms of a condition or substantially preventing the appearance of clinical symptoms of a condition, in a subject in need thereof, said subject being a fetus and said condition being a condition which is caused by magnesium deficiency, and/or which is treatable by an elevated level of magnesium, the method comprising orally administering to a pregnant mother carrying the fetus a therapeutically effective amount of a composition comprising a hydrate form of magnesium oxide, denoted as MgO.(H 2 O)n, at a concentration in a range of from 1 to 100 weight percent (wt %), where n is any value from 0.1 to 2. 
     
     
         11 . The method of  claim 10 , wherein said condition is cerebral palsy. 
     
     
         12 . The method of  claim 10 , wherein orally administering the composition is effected daily. 
     
     
         13 . The method of  claim 10 , wherein an amount of elemental magnesium in said therapeutically effective amount is in a range of from 500 mg to 2000 mg. 
     
     
         14 . The method of  claim 10 , wherein said composition comprises:
 Magnesium oxide hydrate MgO.(H 2 O)n, at a concentration in a range of from 1 to 100 wt %, wherein n in any value from 0.1 to 2, and MgO at a concentration in a range of from 0 to 99 wt %; or   Magnesium oxide hydrate MgO.(H 2 O)n, at a concentration in a range of from 1 to 100 wt %, wherein n in any value from 0.1 to 2, and Mg(OH) 2 , at a concentration in a range of from 0 to 99 wt %; or   Magnesium oxide hydrate MgO.(H 2 O)n, at a concentration in a range of from 1 to 100 wt %, wherein n is any value from 0.1 to 2, and Mg(OH) 2  at a concentration in a range of from 0 to 99 wt %, and MgO, at a concentration in a range of from 0 to 99 wt %.   
     
     
         15 . The method of  claim 10 , wherein n is in a range of from 0.3 to 1. 
     
     
         16 . The method of  claim 10 , wherein a concentration of said MgO.(H 2 O)n in said composition is selected from the group including: at least 10 wt %, at least 20 wt %, at least 30 wt %, at least 40 wt %, at least 50 wt %, at least 60 wt %, at least 70 wt % or at least 80 wt % of a total weight of the composition. 
     
     
         17 . The method of  claim 10 , wherein said composition is in a form of a plurality of particles, and said particles have a BET surface area in a range of from 30 m 2 /gram to 40 m 2 /gram. 
     
     
         18 . The method of  claim 10 , wherein said composition is formulated as a unit dosage form for oral administration, wherein an amount of elemental magnesium in said unit dosage form is in a range of from 50 mg to 2000 mg, wherein said unit dosage form is administered daily. 
     
     
         19 . The method of  claim 10 , wherein said composition is characterized as capable of generating free magnesium ions from at least 50% of said composition under physiological conditions of a human stomach. 
     
     
         20 . The method of  claim 10 , wherein said composition is characterized as generating free magnesium ions from at least 50%, or at least 80%, of said composition when dissolved in an acidic aqueous solution for 45 minutes at room temperature.